Autopsy report · NCT05938725
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Cause of deathFunding or business
“Study discontinued due to sponsor decision.”
Life of this trial
- Registered 7 months before it started.
- Ran for about 3 years 1 month before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Kyverna Therapeutics
- Sponsor type
- Industry
- Conditions
- Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III; Lupus Nephritis - WHO Class IV
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy; Standard lymphodepletion regimen
- Participants
- 6
- Sites
- 6
- Countries
- United States
Trials that died the same way
- Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health
“Funding for this study was discontinued by the sponsor after the first year.” - The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study
“Study discontinued due to lack of study funding.” - Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
“Study was cancelled by Sponsor.” - Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
“Study discontinued due to low accrual.” - Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
“Study discontinued due to futility.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.